Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEP-37247 in lumbosacral radicular pain
NCT01240876Phase 2Completed
- Sponsor
- Cephalon, Inc.
- Start
- Jan 2011
- Primary completion
- Mar 2013
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of placulumab in lumbosacral radiculopathy (6 arms), sponsored by Cephalon, Inc. Primary endpoints: Occurrence of adverse events compared to placebo at 28 weeks and Mean change in the weekly average of daily average pain intensity (API) in the affected leg at 4 weeks. Started Jan 2011; status: completed.
02
Drugs
placulumab
03
Conditions
lumbosacral radiculopathy
Beyond the preview
Go deeper on NCT01240876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01240876.